Ambu® Laryngeal Mask as an Intubation Conduit

Intubation, Endotracheal Clinical Trial

Official title:

The Ambu® Laryngeal Mask as an Intubation Conduit For Patients Undergoing Routine General Anesthesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00272194
• Other study ID #: HSC-MS-05-0347
• Status: Completed
• Phase: Phase 4
• First received: January 2, 2006
• Last updated: March 22, 2016
• Start date: December 2005
• Est. completion date: April 2007

Study information

• Verified date: March 2016
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the Ambu Laryngeal Mask can be used as an intubation conduit for endotracheal intubation.

Description:

The laryngeal mask airway (LMA) is an established supra-glottic device that provides better ventilation than traditional mask ventilation and is less invasive than endotracheal intubation. Being less invasive, it is commonly used for short elective surgical procedures. Its ability to be both easily and rapidly inserted also makes it useful as a rescue device in difficult and failed intubations. Being a supra-glottic device, the LMA does not protect patients from regurgitation and aspiration. Additionally, patients requiring alternative positions, such as prone or lateral, or those having surgery in the neck/head area are contra-indicated for LMA use due to risk of possible movement of the LMA, and therefore possible loss of airway patency. Thus, the LMA can be utilized as an intermediary method of airway management to endotracheal intubation.

The manufacturer of the reusable LMA-ClassicTM states that "the success rate of intubation through the standard LMA-ClassicTM is highly variable (30-93%)," whereas the success rate of the disposable version, LMA-UniqueTM, has been found to be only 21%1. An LMA specifically designed for intubation now exists and improves the success rate of intubation. The reusable LMA-FastrachTM or Intubating-LMATM (ILMA) is a rigid and anatomically curved airway tube. It is wide enough to accommodate 8.0 mm cuffed endotracheal tubes. Attached to the ILMA is a rigid handle to aid in one-handed insertion, removal, and adjustment. Success rates for intubating through the ILMA are 96.5% when inserted blindly and 100% with fiberoptic guidance2. No disposable version of the ILMA presently exists.

The Ambu® Laryngeal Mask (ALMA) is a new disposable laryngeal mask with an anatomical curve similar to the ILMA. The reasons for the use of disposable products can be many and varied. The residual risk of the transmission of germs and protein particles represents one indication. If supra-glottic airway devices are used electively or in emergencies, e.g. for HIV-positive patients or those infected with Creutzfeldt-Jacob disease, reuse of the products is not desirable. Disposable products, on the other hand, offer the benefit that the transmission of germs is avoided, and at the same time offer considerable economic advantages due to the much lower price of the product. The disposable ALMA has been proven as an effective and safe supra-glottic airway device3. Upon fiberoptic visualization through its shaft, the glottis was visualized 91.5% of the time, indicating that this device may be used as an intubation conduit. The purpose of this study is to determine if the ALMA is also safe and effective as an intubating conduit. The hypothesis is that the ALMA will perform as well as, if not better than the LMA-UniqueTM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: April 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• The patient is ASA 1-3 presenting for an elective surgical procedure

• The patient is 18-65 years of age

• The patient weighs > 50 kg with a BMI < 30 kg/m2

• The patient has a Mallampati grade I -III airway

• The patient is undergoing general anesthesia with controlled ventilation for minor routine surgical procedures

• The period of anesthesia time is >30 minutes

Exclusion Criteria:

• The patient is an ASA classification 4

• The patient is < 18 or >65 years of age

• The patient weighs < 50 kg or has a BMI > 30 kg/m2

• The patient has a history of inadequate cervical mobility

• The patient has a history or signs of difficult airway management

• The patient has a Mallampati grade IV Class airway

• The patient has a mouth opening < 2.5 cm

• The patient has an oral cavity disease

• The patient has a cervical malformation

• The patient had upper respiratory tract symptoms in the previous 10 days

• The patient is to have surgery performed to the head/neck or thoracoabdominal cavities needing to be paralyzed, or in the lateral/prone position

• The patient is considered at risk of aspiration (non-fasted, gastroesophageal reflux/disease)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind

Related Conditions & MeSH terms

• Intubation, Endotracheal

Intervention

Device:
• Ambu Laryngeal Mask

• Aintree Exchange Catheter

• Laryngeal Mask Airway

Locations

Country	Name	City	State
United States	Memorial Hermann Hospital	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston	AMBU

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time and number of attempts required; Level of difficulty; Degree of irritation of the pharynx, epiglottis, and arytenoids
Secondary	vital signs, oxygen saturation, end-tidal carbon dioxide